Mark Baglin

Mark Baglin is the Chief Commercial Officer of F2G. He brings substantial experience with commercial and franchise leadership in the biopharmaceutical industry, which he will bring to bear in building and leading global commercial teams toward launch and beyond in the rare fungal disease space. Prior to joining F2G, Mark was Senior Vice President, Head of Marketed Products, at Alnylam Pharmaceuticals, responsible for all in-line and late-stage franchise and program teams in the rare disease space. Prior to that experience, he was Vice President, Head of Global Marketing and Commercial Strategy, building and leading the Marketing and Market Access teams that executed three global launches. Before joining Alnylam, Mark was Head of Shire’s $1.5 billion HAE franchise, which he helped build over 7 years in roles of increasing responsibility, including two external acquisitions. Prior to joining Shire, he gained experience with several small and large pharmaceutical and medical device companies in both local and global commercial roles.

Mark holds a bachelor of commerce (BCom) degree from the University of Birmingham, UK.